Share |
 
SFDA approval filed for TPIAO label extension
User Rating: / 0
PoorBest 
Written by Shenyang, China   
Wednesday, 21 January 2009
3SBio Inc. announced the filing of approval for TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) with the Chinese State Food and Drug Administration (SFDA) on December 30, 2008. 

TPIAO for ITP will be the only treatment of its kind available in China, if the extension is approved. The aim of this filing is to extend the label of TPIAO for use in the treatment of ITP.
Comments
Search RSS
Only registered users can write comments!
A Product of IT Mahal Pvt.Ltd.

All rights reserved."
 
[ Back ]